

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049994 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 471/06 (2006.01)
C07D 405/14 (2006.01) C07D 498/06 (2006.01)
C07D 409/14 (2006.01) C07D 519/00 (2006.01)
C07D 419/14 (2006.01) A61P 35/00 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/044798

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

30 August 2024 (30.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:

63/579,540 30 August 2023 (30.08.2023) US

(71) Applicant: **ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS** [US/US]; 2500 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US).

(72) Inventors: **ZHANG, Xuqing**; c/o Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs, 2500 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US). **ROACH, Jeremy**; c/o Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs, 2500 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US). **DENG, Qiaolin**; c/o Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs, 2500 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US). **PRIESTLEY, E. Scott**; c/o Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs, 2500 Renaissance Boulevard, King of Prussia, Pennsylvania 19406 (US).

(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF

(57) Abstract: Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).

WO 2025/049994 A1